Fruquintinib Plus Capecitabine Versus Bevacizumab Plus Capecitabine as Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer

NCT04733963 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

112

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer

Interventions

DRUG: Fruquintinib Plus Capecitabine
DRUG: Bevacizumab Plus Capecitabine

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University